Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT00443326
First received: March 1, 2007
Last updated: January 17, 2014
Last verified: January 2014

March 1, 2007
January 17, 2014
March 2007
December 2008   (final data collection date for primary outcome measure)
Psoriatic Assessment Score Index [ Time Frame: First 85 Days ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00443326 on ClinicalTrials.gov Archive Site
Safety and Tolerability [ Time Frame: Collected for 300 Days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects
A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of AMG 714 After Multiple Dose Administration in Subjects With Moderate to Severe Psoriasis

Investigational drug AMG 714 will be given to 66 subjects with moderate to severe psoriasis to study safety, pharmacokinetics, and efficacy. Dose levels include 150mg and 300mg and will be given to each subject for a total of 6 doses. Each dose for each subject will be given once every 2 weeks. Subjects will followed for up to 300 days post the first dose of AMG 714.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Psoriasis
Drug: AMG 714
Dosing Regimen is 6 Doses over 3 Months
Experimental: AMG 714
AMG 714 will be given as a multiple dose regimen
Intervention: Drug: AMG 714
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
22
May 2010
December 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Active but clinically stable, plaque psoriasis.
  • Psoriasis involving greater than or equal to 10% of the body surface area
  • A minimum PASI score of 10 obtained during the screening period.
  • Received at least one previous phototherapy or systemic psoriasis therapy or have been a candidate to receive phototherapy or systemic psoriasis therapy in the opinion of the investigator.
  • At least 18 years of age.
  • Heterosexually active men and women must be willing to practice an effective method of contraception (as outlined in section 6.7) as determined by the investigator and sponsor for the duration of the study. This includes any washout period and the follow-up period.
  • ALT and AST less than or equal to 2 x the upper limit of normal; hemoglobin greater than or equal to 10 g/dL (greater than or equal to 100 g/L in SI units); platelet count greater than or equal to 125,000 mm3 (greater than or equal to 125 x109/L in SI units); white blood cell count greater than or equal to 3,500 cells/mm3 (greater than or equal to 3.5 x109/L in SI units); serum creatinine less than or equal to 2 mg/dL (less than or equal to 177 μmol/L in SI units).
  • Negative for HIV antibodies, hepatitis B surface antigen, and hepatitis C antibodies.
  • Capable of understanding and giving written, voluntary informed consent before study screening.

Exclusion Criteria:

  • Active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit.
  • Evidence of skin conditions (eg, eczema) at the time of the screening visit or between the screening visit and study drug initiation that would interfere with evaluations of the effect of investigational product on psoriasis.
  • Clinically significant adverse event, infection, or laboratory toxicity, at the time of the screening visit or between the screening visit and study drug initiation that in the opinion of Amgen or the Investigator would preclude participation in the study.
  • Clinically significant infection less than or equal to 30 days before the screening visit that in the opinion of Amgen or the Investigator would preclude participation in the study.
  • Known positive tuberculin skin test (if not treated with appropriate chemoprophylaxis) or recent (within 6 months) exposure to a patient with active tuberculosis.
  • Any other known infectious process that would, in the investigator's discretion, interfere with the subject's ability to participate in the study.
  • Significant concurrent medical conditions at the time of screening, including:
  • Uncontrolled hypertension (defined as screening systolic blood pressure measurement of greater than 160 mm Hg or a screening diastolic blood pressure of greater than 100 mm Hg) confirmed by 2 separate measurements during the screening visit
  • Myocardial infarction less than or equal to 52 weeks before the screening visit
  • Unstable angina pectoris
  • Congestive heart failure
  • Steroid or oxygen dependent chronic obstructive pulmonary disease
  • Diagnosis of multiple sclerosis or any other demyelinating disease
  • Inadequately controlled diabetes mellitus, defined by glycohemoglobin greater than 7.0 at screening
  • History of cancer (other than resected and surgically cured cervical cancer, cutaneous basal cell, squamous cell carcinoma) less than or equal to 5 years before the administration of first dose of investigational product
  • Open cutaneous ulcers
  • Any condition that, in the judgment of the investigator, might cause this study to be detrimental to the subject.
  • Any evidence during screening of cutaneous basal or squamous cell carcinoma, or melanoma.
  • Current or history of psychiatric disease that would interfere with the ability to comply with the study protocol or give informed consent.
  • History of alcohol or drug abuse that would interfere with the ability to comply with the study protocol.
  • Previous receipt of etanercept or any other anti-TNF agent(s), alefacept, efalizumab, or other investigational biologic agent for psoriasis.
  • Receipt of any investigational product(s) less than or equal to 30 days before the first dose of investigational product in this study.
  • PUVA therapy less than or equal to 30 days before the first dose of investigational product.
  • UVA therapy less than or equal to 14 days before the first dose of investigational product.
  • UVB therapy less than or equal to 30 days before the first dose of investigational product.
  • Receipt of any other systemic psoriasis therapy or oral or parenteral corticosteroids less than or equal to 14 days before the first dose of investigational product.
  • Topical steroids, topical vitamin A or D analog preparations or anthralin less than or equal to 14 days before the first dose of investigational product (exception - topical steroids at no higher than moderate strength, according to the package insert, are permitted on the scalp, axillae, and groin).
  • Topical cyclosporin or calcineurin inhibitors such as pimecrolimus (Elidel) and tacrolimus (Protopic) less than or equal to 14 days before the first dose of investigational product.
  • Intravenous or oral calcineurin inhibitors such as tacrolimus (Prograf) less than or equal to 30 days before the first dose of investigational product.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00443326
20060349
Not Provided
Amgen
Amgen
Not Provided
Study Director: MD Amgen
Amgen
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP